Clinical Trial Update: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of HuMab-5B1 (MVT-5873) in CA19-9 positive malignancies, including pancreatic cancer, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• HuMab-5B1 (MVT-5873) (HuMab-5B1)

Snippet

Sponsor: BioNTech Research & Development, Inc. | Conditions: Pancreatic Cancer | Phase 1 | Status: TERMINATED